Idexx Laboratories · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← IDXX

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	1.22	+9.7%	64.0%	0.43	0.34	27.8%	0.32	4.27	0.35	—
FY2026 Q1	2026-03-31	1.14	+14.3%	63.4%	0.36	0.28	24.4%	0.23	3.47	0.35	—
FY2025 Q4	2025-12-31	1.09	+14.3%	60.3%	0.32	0.25	22.8%	0.33	3.09	0.24	—
FY2025 Q3	2025-09-30	1.11	+13.3%	61.8%	0.35	0.27	24.8%	0.37	3.40	0.24	—
FY2025 Q2	2025-06-30	1.11	+10.6%	62.6%	0.37	0.29	26.5%	0.15	3.63	0.34	—
FY2025 Q1	2025-03-31	1.00	+3.6%	62.4%	0.32	0.24	24.3%	0.21	2.96	0.40	—
FY2024 Q4	2024-12-31	0.95	+5.8%	59.8%	0.26	0.22	22.7%	0.23	2.62	0.25	—
FY2024 Q3	2024-09-30	0.98	+6.6%	61.1%	0.30	0.23	23.9%	0.19	2.80	0.22	—
FY2024 Q2	2024-06-30	1.00	+6.4%	61.7%	0.26	0.20	20.3%	0.22	2.44	0.22	—
FY2024 Q1	2024-03-31	0.96	+7.1%	61.5%	0.30	0.24	24.4%	0.17	2.81	0.15	—
FY2023 Q4	2023-12-31	0.90	+8.8%	58.4%	0.25	0.19	21.6%	0.22	2.31	0.04	—
FY2023 Q3	2023-09-30	0.92	+8.8%	59.9%	0.28	0.21	23.2%	0.24	2.53	0.04	—
FY2023 Q2	2023-06-30	0.94	—	60.7%	0.30	0.22	23.8%	0.17	2.67	0.00	—
FY2023 Q1	2023-03-31	0.90	—	60.3%	0.28	0.21	23.8%	0.14	2.55	0.00	—
FY2022 Q4	2022-12-31	0.83	—	58.5%	0.23	0.17	20.8%	0.12	2.05	0.07	—
FY2022 Q3	2022-09-30	0.84	—	60.2%	0.24	0.18	21.5%	0.15	2.15	0.17	—

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.